Device Trial Radar · NCT07654491
Withings HFRN Retrospective Study
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
9,000
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- WithingsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 120 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a fully decentralized retrospective, non-interventional study evaluating the diagnostic performance of the Withings Heart Function Risk Notification (HFRN), a software-only medical device (SaMD)
Conditions
- Heart Failure
Interventions
Withings Heart Function Risk Notification (HFRN)Device
Software-only medical device (SaMD)
Claims-based heart-failure adjudication (reference standard)Other
Ground-truth heart-failure case / control status derived from administrative claims by a deterministic, pre-specified rule set.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity (Se) of the HFRN algorithmTime frame: 13 weeks
- Specificity (Sp) of the HFRN algorithmTime frame: 13 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Withings (Sponsor) - Decentralized Retrospective Study, No Physical Sites
Issy-les-Moulineaux, Île-de-France Region, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.